HLFHERBALIFE LTD.
Wholesale-Drugs, Proprietaries & Druggists' Sundries
- Revenue
- $5.0B
- 0.9% YoY
- Operating margin
- 9.5%
- 24% YoY
- EBITDA
- $602M
- 19% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 2.3×
- $1.4B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear146% of net incomeCash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear2% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear4% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $5.8B | $5.2B | $5.1B | $5.0B | $5.0B | 0.9% |
| Operating income | $734M | $545M | $356M | $386M | $481M | 25% |
| Net income | $447M | $321M | $142M | $254M | $228M | 10% |
| Operating cash flow | $460M | $353M | $358M | $285M | $333M | 17% |
| Capex | $151M | $156M | $135M | $122M | $80M | 34% |
| Stock-based comp | $54M | $44M | $48M | $50M | $44M | 12% |
| Buybacks | $1.0B | $147M | $11M | $8M | $8M | 1.2% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.